Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apotex Plavix Saga May Finally Be Over; Judge Asks “What Is Going On In This Case?”

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex sought $3.4 billion in damages, claiming Bristol-Myers Squibb scuttled their patent settlement agreement by submitting a false certification to the FTC that it had no oral commitment not to sell an authorized generic of Plavix during Apotex’s exclusivity period; Apotex had told the FTC there was such a side deal.

You may also be interested in...

FTC’s Last Stand On Pay-For-Delay Deals? Supreme Court To Make Call On Legality

The high court will determine whether brand-generic reverse payments to settle patent disputes are presumptively anticompetitive and unlawful when it takes up FTC v. Actavis; a ruling affirming the lower court would enable companies to enter agreements without the threat of litigation.

Apotex To Retain About $300 Million From Its At-Risk Launch of Generic Plavix

A judge sets damages at 50% of Apotex's net sales of generic clopidogrel plus prejudgment interest of $107.9 million.

True Confessions: Bristol Exec Sentenced To Write A Book, But Can He Get Published?

Former Bristol-Myers Squibb executive Andrew Bodnar may have escaped jail time for lying to the Federal Trade Commission, but he may suffer, nonetheless. Publishers and authors say his unusual sentence to write a book about his experience will bring plenty of pain and humiliation

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts